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Optimal Left Ventricular Endocardial
Pacing Sites for Cardiac Resynchronization Therapy
in Patients With Ischemic Cardiomyopathy
David D. Spragg, MD,* Jun Dong, MD, PHD,*† Barry J. Fetics, MS,* Robert Helm, MD,*
Joseph E. Marine, MD,* Alan Cheng, MD,* Charles A. Henrikson, MD,* David A. Kass, MD,*
Ronald D. Berger, MD, PHD*
Baltimore and Silver Spring, Maryland
Objectives We sought to investigate the impact of left ventricular (LV) pacing site on mechanical response to cardiac resyn-
chronization therapy (CRT) in patients with ischemic cardiomyopathy (ICM).
Background CRT reduces morbidity and mortality in patients with dyssynchronous LV failure; however, variability in response,
particularly in ICM patients, poses ongoing challenges. Endocardial biventricular (BiV) stimulation may provide
more flexibility in LV site selection and yield more natural transmural activation patterns. Whether this applies to
ICM and whether optimal LV endocardial pacing locations vary among ICM patients remain unknown.
Methods Peak rate of LV pressure increase (dP/dtmax) was measured at baseline, during VDD pacing at the right ventricu-
lar apex, and during BiV pacing from the right ventricular apex and 51  14 different LV endocardial sites in
patients with ICM (n  11). Seven patients already had an epicardial LV lead (CRT) in place, allowing compari-
son of epicardial BiV stimulation with that using an endocardial site directly transmural to the CRT-coronary si-
nus lead tip. Electroanatomic 3-dimensional maps with color-coded dP/dtmax response defined optimal pacing
regions delivering 85% of maximal increase in dP/dtmax.
Results Endocardial BiV pacing improved dP/dtmax over right ventricular apex pacing in all patients (mean increase 241  38
mm Hg/s; p  0.0001). In patients with pre-existing CRT leads, LV endocardial versus epicardial pacing at transmural
sites yielded equivalent dP/dtmax values. However, dP/dtmax at the best endocardial site exceeded that achieved with
the pre-implanted CRT device (mean increase 111  25 mm Hg/s; p  0.004). An average of 2 optimal endocar-
dial sites were identified for each patient, located at the extreme basal lateral wall (8 of 11 patients) and other re-
gions (9 of 11). Standard mid-LV free wall pacing yielded suboptimal LV function in 73% of patients. Optimal pacing
sites were typically located in LV territories remote (9.3  3.6 cm) from the infarct zone.
Conclusions CRT delivered at best LV endocardial sites is more effective than via pre-implanted coronary sinus lead pacing.
The location of optimal LV endocardial pacing varies among patients with ICM, and individual tailoring may im-
prove CRT efficacy in such patients. (J Am Coll Cardiol 2010;56:774–81) © 2010 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.014u
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ieft ventricular (LV) systolic dysfunction is frequently
ompounded by dyssynchronous ventricular activation, re-
ulting in an array of hemodynamic, structural, and molec-
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ccepted June 15, 2010.lar changes that worsen clinical outcomes in affected
atients (1–5). Cardiac resynchronization therapy (CRT)
everses many of these derangements (6,7), and reduces
orbidity and mortality in patients with dyssynchronous
V failure (8–10). Although clinically effective in most
atients, CRT confers little or no therapeutic benefit to a
ubstantial minority (20% to 50%) (11).
See page 782
Failure of CRT may be due to a variety of factors,
ncluding inappropriate patient selection, inability to place
n LV pacing lead due to unfavorable coronary sinus (CS)
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August 31, 2010:774–81 Effective LV Endocardial Pacing Sites for CRTnatomy, or implantation of the CS lead at a suboptimal
osition. Traditionally, CRT has been delivered by LV
acing through a lead placed in a posterolateral tributary of
he CS. Patients with ischemic cardiomyopathy (ICM) are
ess likely to benefit from CRT compared with their
onischemic counterparts (12–14), due perhaps to the
ffects of scar burden and variable distribution of optimal
V pacing sites in ischemic patients. Data regarding the
deal location for CS lead placement remain limited, with
ublished studies performed predominantly in experimental
odels or in patients with nonischemic cardiomyopathy (15–17).
We hypothesized that patients with ICM may demon-
trate a high degree of interpatient heterogeneity in LV
acing site locations yielding maximal CRT efficacy, and
hat optimal pacing sites may frequently occur in regions
ther than the posterolateral left ventricle. To test this
ypothesis, we studied the acute CRT effect in a series of
atients with ICM, performing biventricular (BiV) pacing
rom the right ventricular apex (RVA) coupled with 50
ifferent LV endocardial pacing sites in each patient. As
ndocardial pacing has itself been recently suggested to
nhance a BiV stimulation effect over traditional LV epi-
ardial stimulation (18), we further compared the two at the
ame location in a subset of patients with a pre-existing CS
ead.
ethods
atient selection. All patients included in the study were
equired to have ICM, severe LV systolic dysfunction
ejection fraction 35%) despite appropriate medical man-
gement, and evidence of dyssynchronous ventricular acti-
ation. All patients were referred for LV tachycardia or
remature ventricular complex ablation, with the pacing
rotocol performed in conjunction with electrophysiological
tudy and anticipated ablation, thereby allowing catheter
lacement in the left ventricle. All patients consented to the
nvestigation, and the protocol was approved by the Johns
opkins institutional review board.
acing protocol. CATHETER PLACEMENT. All patients un-
erwent placement of standard electrophysiological pacing
atheters at the high right atrium and RVA, as well as
lacement of a roving ablation catheter with a 3-dimensional
osition sensor (ThermoCool, Biosense Webster, Inc., Dia-
ond Bar, California) in the left ventricle. Right atrial and
ight ventricular catheters were introduced through 6-F venous
ccess sheaths in usual fashion and were used in conjunction
ith standard electrophysiology stimulators and recording
evices (EP Med Systems, Inc., West Berlin, New Jersey). The
V catheter was introduced either through an 8-F arterial
heath and advanced retrograde across the aortic valve (n 6)
r by 8-F venous access using a transseptal approach and
dvanced across the mitral valve (n 5). The LV catheter was
sed in conjunction with a standard electroanatomic mapping
ystem (Carto XP, Biosense Webster, Inc.). A Millar pigtail
atheter (Millar Instruments, Houston, Texas) was placed mhrough a 7-F arterial sheath and
dvanced retrograde across the
ortic valve into the LV cavity (n
10) or through a transseptal
pproach across the mitral valve (n
1). The Millar catheter was
inked to a custom-designed data
cquisition platform for collection
f LV pressure and digital calcula-
ion of peak rate of left ventricular
ressure increase (dP/dtmax).
ENTRICULAR PACING. The
ight atrial, right ventricular, and
V catheters were connected to a
emporary pacemaker capable of
DD pacing (Medtronic, Inc.,
inneapolis, Minnesota). Pacemaker output was delivered
hrough a customized splitter that allowed for simultaneous
acing through the right ventricular apical catheter and the
oving LV catheter. Pacing was typically performed at 5 mA,
lthough higher outputs for pacing in regions of diseased
yocardium were occasionally required. A single fixed atrio-
entricular (AV) delay was used throughout the study; the ideal
V delay was determined at the onset of the study, and was
efined as the longest AV delay that allowed for ventricular
acing without evidence of fusion with native conduction.
alues for dP/dtmax were recorded during baseline rhythm
normal sinus rhythm in 10 of 11; atrial fibrillation in 1 of 11),
nd during VDD-RVA pacing at study onset, study conclu-
ion, and 1 to 2 times during the protocol to document stable
V function over the course of the investigation. dP/dtmax
alues were recorded during VDD-BiV pacing (atrial-sensed,
VA, and LV paced) at approximately 50 different LV sites
51  14 sites). At each LV pacing site, endocardial bipolar
lectrogram voltage data were collected, and LV capture
hrough the roving catheter was confirmed for 8 to 10 beats
efore initiation of BiV pacing and collection of dP/dtmax data
collected over 15 to 20 beats). In patients with a CRT system
n place, dP/dtmax values were also obtained during CRT
acing through the device at identical AV delays used in the
tudy protocol. In those patients, endocardial sites directly
ransmural to the distal pole of the CS lead were identified, and
P/dtmax was assessed at those points as well.
ap generation. An electroanatomic mapping system
Carto XP) was used to collect 3-dimensional location and
isplay hemodynamic data at each LV site. Bipolar voltage,
ctivation, and dP/dtmax maps were generated. Values for
P/dtmax were converted to a color-coded scale, allowing
ustomized high-density mapping of LV systolic function
ersus endocardial pacing site. At each point, dP/dtmax
alues were derived from an averaged series of paced beats
typically 15 to 20) using customized software.
nalysis of scar and optimal pacing site locations. In-
arct, optimal pacing region, and total LV areas were
Abbreviations
and Acronyms
AV  atrioventricular
BiV  biventricular
CRT  cardiac
resynchronization therapy
CS  coronary sinus
dP/dtmax  peak rate of
left ventricular pressure
increase
ICM  ischemic
cardiomyopathy
LV  left ventricular
RVA  right ventricular
apexeasured (Carto XP). Scar was defined by endocardial
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Effective LV Endocardial Pacing Sites for CRT August 31, 2010:774–81ipolar voltage assessment, with cutoff values of 1.5 and 0.5
V for diseased tissue and dense scar, respectively. Optimal
acing regions were defined as those regions yielding 85%
f the peak achievable increase in dP/dtmax over baseline
VA pacing (i.e., [(dP/dtmax site)  (dP/dtmax RVA)]/
(dP/dtmax peak)  (dP/dtmax RVA)] 0.85). Distances
etween pacing sites and the infarct center were determined
sing curvilinear measurements over the LV endocardial
urface (Carto XP) and expressed both as linear surface
istance (in centimeters) and as a percentage of the total LV
ircumference in the plane of measurement.
tatistical analysis. Data are presented as mean  SD.
omparisons of dP/dtmax values between pacing modes (base-
ine RVA pacing, BiV pacing, device-based epicardial LV
acing) were performed with paired 2-tailed Student t tests.
he coefficient of variation for baseline dP/dtmax measure-
ents was calculated for each patient as (SD/mean)·100.
esults
leven patients (all male, age 68  5 years) were studied
etween February 2006 and September 2009. Baseline
linical data are provided in Table 1. All had dyssynchro-
ous LV systolic failure due to ICM (mean ejection fraction
8  5%), with symptoms from New York Heart Associ-
tion functional class I to III despite optimal medical
herapy. Patients were referred for mapping and ablation of
onomorphic ventricular tachycardia (10 of 11 patients) or
ymptomatic premature ventricular complexes (1 of 11
atients). The determination of LV dyssynchrony was based
n surface electrocardiography with or without tissue Dopp-
er echocardiography. Nine patients had left bundle branch
linical CharacteristicsTable 1 Clinical Characteristics
Age, yrs 68 5.6
Male 11 (100)
Ejection fraction 18 5.1
Ischemic cardiomyopathy 11 (100)
New York Heart Association functional class
I 1 (9)
II 5 (45)
III 5 (45)
QRS morphology
Left bundle branch block 9 (82)
Intraventricular conduction defect 1 (9)
Right bundle branch block 1 (9)
QRS duration, ms 176 29
Cardiac resynchronization therapy device 7 (64)
Rhythm
Normal sinus rhythm 7 (64)
Atrial paced 1 (9)
Ventricular paced 2 (18)
Atrial fibrillation 1 (9)
Electrophysiological indication
Ventricular tachycardia 10 (91)
Premature ventricular complexes 1 (9)lalues are mean  SD or n (%).lock (QRS duration 178  26 ms), 1 had an interventric-
lar conduction delay pattern with mechanical dyssynchrony
oted on echocardiography (QRS duration 131 ms; tissue
oppler imaging 80 ms between septal and lateral wall
ctivation), and 1 had right bundle branch block (QRS
uration 200 ms). Seven patients had a CRT BiV pacing
ystem in place at the time of study enrollment.
emodynamic response. Mean resting dP/dtmax was
80  115 mm Hg/s in native rhythm and 677  178 mm
g/s during RVA pacing. dP/dtmax during RVA pacing
emained stable throughout the protocol (average coefficient
f variation of 7.6%), showing that other comparisons were
eing made under steady-state conditions.
Resynchronization with BiV VDD pacing from the RVA
nd LV endocardial sites improved LV mechanical function
n all patients (Fig. 1), with an average peak increase in
P/dtmax of 36% (241  38 mm Hg/s) compared with
aseline RVA pacing alone (p  0.0001). In the 7 patients
ith CRT systems already in place, we found that dP/dtmax
alues arising from pacing at LV endocardial sites yielding
eak results were higher than those from pacing through the
mplanted CRT system (13% increase; 110  65 mm
g/s; p  0.0042).
One potential reason for the disparate effects of endocar-
ial BiV pacing versus implanted CRT (CS pacing) was the
V surface being paced rather than the LV region being
aced. To test this, we compared the hemodynamic effect of
V endocardial pacing using a site immediately transmural
o the CS lead tip with the effect from device-based
picardial LV pacing (Fig. 2). The dP/dtmax response was
imilar whether LV pacing was endocardial or epicardial
923  234 mm Hg/s vs. 877  278 mm Hg/s, respectively
p  0.5]), suggesting that the maximal enhanced response
een with endocardial stimulation was more likely due to
ccessing ideal LV pacing sites rather than to endocardial
timulation per se.
apping the optimal site. Classically, CRT has been
hought best achieved through lateral or posterolateral
ree-wall LV pacing. We found, however, that pacing at
raditionally accepted LV pacing sites (mid-lateral LV)
esulted in suboptimal LV systolic function in the majority
f patients (8 of 11) (Fig. 3A). Rather, the most reproduc-
ble spot for optimization of LV function (i.e., sites yielding
85% peak increase in dP/dtmax) appeared to be immedi-
tely below the mitral valve ring, typically in the anterolat-
ral or lateral wall (8 of 11 patients) (Fig. 3B). Rather than
single pacing site, 9 of 11 patients had 2 noncontiguous
ites yielding optimal hemodynamic results (Fig. 3A). Op-
imal pacing regions had an average area of 13  13 cm2 or
.2  4.4% of total LV endocardial surface area. dP/dtmax
nd voltage maps from all patients are presented in the
nline Appendix.
Systematic analysis of optimal pacing site location was
erformed by schematically segmenting the LV into 9
egions: anterior, lateral, inferior, and septal base; anterior,
ateral, inferior, and septal mid-wall; and apex. Among the
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ielding optimal function. These sites were located predom-
nantly but not exclusively at lateral and anterior regions
Fig. 4, Online Appendix). Optimal pacing sites were never
ound on the inferior LV wall.
car versus optimal site location. To determine the in-
uence of infarct size and location on the corresponding
ffectiveness and location of optimal LV endocardial pacing
ites, scar area and scar-pacing site distance were measured
sing CartoXP software. The average infarct size was
27.6  43 cm2 or 25.8  14.9% of the total LV
ndocardial area. Optimal pacing sites were typically located
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Figure 1 Left Ventricular Systolic Function During Native Rhyth
(A) Raw peak rate of left ventricular pressure increase (dP/dtmax) values during ba
and pacing through the implanted cardiac resynchronization therapy (CRT) device.
baseline value. NSR  normal sinus rhythm.ar from infarct centers (9.3  3.6 cm; 37% of coplanar LV mircumference) and were located in healthy myocardium
bipolar voltage 1.5 mV) in 10 of 11 patients. In the 7
atients with CRT leads in place, distance from the lead tip
o the scar center was similarly large (8.3  3.2 cm; 34% of
oplanar circumference), suggesting that distance alone did
ot result in peak achievable dP/dtmax. There was no effect
f scar size on dP/dtmax response to BiV pacing (either peak
P/dtmax achievable or peak increase over baseline) or on the
ize and number of optimal LV endocardial pacing sites.
ctivation versus optimal site location. To investigate
hether baseline patterns of LV activation correlated with
ptimal LV pacing site location, endocardial LV activation
VDD-BiV
pacing
CRT device
pacing
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Patient 7
Patient 8
Patient 9
Patient 10
Patient 11
VDD-BiV
pacing
CRT device
pacing
d Ventricular Pacing
rhythm, VDD-right ventricular apex (RVA) pacing, VDD-biventricular (BiV) pacing,
rcentage of change in dP/dtmax values, with VDD-RVA pacing serving as them an
seline
(B) Peaps were constructed for all patients (Online Appendix).
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Effective LV Endocardial Pacing Sites for CRT August 31, 2010:774–81ctivation maps were generated during sinus rhythm (n  8),
trial fibrillation (n  1), or RVA pacing (due to hemody-
amically significant bradycardia; n  2). LV activation
uration in our series was prolonged (135  44 ms), with
atest activation at the left lateral free wall in 9 patients and
t other regions in the remaining 2. In 8 of 11 patients,
ptimal pacing sites were located at regions other than the
atest activated site (Online Appendix), whereas in 3 pa-
ients, optimal function was achieved by pacing the latest
ctivated myocardium.
iscussion
o our knowledge, the current study presents the first
ystematic analysis of optimal endocardial LV pacing site
ocation for CRT in patients with ICM. Our principal
ndings—that mid-left lateral free wall LV pacing resulted
n suboptimal LV mechanical function in the majority of
atients and that LV pacing at extreme basal positions was
ssociated with a peak acute CRT response—have clear
mplications for how best to deliver resynchronization ther-
py in these patients. In addition, our report contributes to
growing body of data about the merits of endocardial
ersus epicardial LV pacing, the impact of scar burden on
RT response, and the impact of interpatient variability in
ptimal LV pacing site location.
Nonresponder rates to CRT continue to hover between
0% and 50%, depending on the metrics used to quantify
RT effect (11). Positioning of the CS lead is one impor-
ant variable governing resynchronization response. Based
n early work from Butter et al. (17), CRT typically is
elivered through a lead positioned in a lateral or postero-
ateral CS tributary, midway between the base and apex of
he ventricle. Our results suggest that in patients with ICM
Figure 2 Catheter Positions During Pacing Protocol
Fluoroscopic right anterior oblique (RAO) and left anterior oblique (LAO) views dem
point immediately transmural to a previously implanted epicardial coronary sinus le
lar catheters was achieved by double transseptal puncture.he traditionally accepted pacing site may not, in fact, yield dhe best mechanical results. The mid-lateral free wall of the
V, although better than baseline RV apical pacing, was
onsistently associated with suboptimal dP/dtmax values in
ur patient series. In contrast, pacing at the extreme base of
he left ventricle, at a position adjacent to the mitral valve
ing, was associated with superior mechanical results in 8 of
1 patients. This region provides logistical challenges for
table CS lead positioning. However, as active fixation CS
eads become more widely used in clinical practice (19),
lacing leads in an extreme basal position may become more
easible.
Although extreme basal LV pacing gave good results in a
lear majority of patients, stimulation at that site still gave
oor results in 27% of our cohort, which (if extrapolated to
ong-term response) would do little to improve the CRT
onresponder rate. A striking finding in our series was the
igh degree of interpatient variability in optimal pacing site
ocation. This finding was documented by Derval et al. (15)
n a recent study of non-ICM patients using a protocol
imilar to ours and suggests that tailored CRT (i.e., patient-
pecific determination of optimal LV lead position at the
ime of device implantation) may be necessary to increase
linical response rates still further. One limitation to tailored
herapy is the restriction imposed by CS tributary anatomy
n lead positioning. This limitation, in part, has driven an
nterest in LV endocardial pacing for resynchronization
herapy.
Our study contributes important new information about
he feasibility of LV endocardial pacing for CRT (20–22).
irst and foremost, we demonstrate that LV endocardial
acing in patients with ICM is capable of dramatic im-
rovements in LV systolic function when the optimal site is
timulated. The patients in our series had average baseline
ting catheter placement, with data sampling at a left ventricular (LV) endocardial
lack arrow). Note that in this case ventricular access with the LV pacing and Mil-onstra
ad (bP/dtmax values of 675 mm Hg/s, suggesting a series of
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urthermore, scar burden in our patients was high, with an
verage scar area encompassing 25% of the total LV area.
espite the severity of disease in this series, LV endocardial
LAO
dP/dt 
max
MV
Voltage
MVA
Patient A
Voltage
dP/dt max
MVA
MVA
848 
596 
A
B
Figure 3 LV Maps of Voltage (Native Rhythm) and Systolic Fun
(A) Left ventricular (LV) voltage (top) and peak rate of left ventricular pressure inc
left lateral (LL) projections. Voltage mapping shows a large inferior scar (red/gray
pacing regions giving optimal dP/dtmax values (purple), including 1 region at the e
mechanical function (orange/green, white arrows). Scale values in dP/dtmax map
cance, but not relevant to the investigational protocol. (B) LV voltage (top) and dP
optimal LV endocardial pacing sites at the extreme LV base. Note that this finding
expressed in mm Hg/s. Points tagged with colored balls were of clinical significanacing resulted in an average improvement in dP/dtmax of l6%, providing clear evidence that endocardial pacing is
apable of delivering striking mechanical results, even in
atients with very poor baseline function.
Some investigators have postulated that for any given
    LL
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atient B Patient C
MVA MVA
MVA MVA
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408
(Biventricular Pacing)
(dP/dtmax) (bottom) maps from a single patient in left anterior oblique (LAO) and
viable anterolateral myocardium (purple). dP/dtmax mapping shows 2 distinct
LV base (gray arrows). Pacing at the mid-LV free wall resulted in suboptimal LV
expressed in mm Hg/s. Points tagged with colored balls were of clinical signifi-
x (bottom) maps from 3 different patients, all in left lateral projection, showing
ndependent of scar location (red) in the voltage maps. dP/dtmax scale values are
t not relevant to the study protocol. MVA  mitral valve annulus.A
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Effective LV Endocardial Pacing Sites for CRT August 31, 2010:774–81e superior to epicardial pacing for CRT (18). We did not
nd this to be the case. Seven of our patients had long-term
RT systems in place, allowing for direct comparison of
ndocardial versus epicardial pacing in patients with dys-
ynchronous failure. Our finding that the mechanical effect
rom LV endocardial and epicardial sites was comparable is
ore consistent with the work of Derval et al. (15) (who
eported similar endocardial and epicardial results) than the
ork of van Deursen et al. (18) (who reported improved
echanical effects from endocardial pacing). The disparity
etween our results and those of van Deursen et al. (18)
ikely stems from the substrate being paced. Our investiga-
ion was performed in subjects with dyssynchronous heart
ailure, whereas van Deursen et al. (18) studied a canine
odel of dyssynchrony without superimposed LV systolic
ailure. We showed previously that dyssynchrony and heart
ailure independently have deleterious effects on parameters
ncluding expression of gap junction proteins (4), cell-cell
oupling (5,23), and conduction velocity (5,23). These
hanges were most pronounced at the endocardial level in
egions of latest myocardial activation. It is likely that
acing healthy endocardium may indeed result in more
apid and efficient LV myocardial activation, with attendant
ncreases in dP/dtmax. Our investigation, however, sheds
ight on the limitations of endocardial pacing in a diseased
ubject.
Using the Carto mapping system, we were able to
elineate regions of scar and investigate whether scar burden
r distribution had any appreciable effect on optimal pacing site
ocation. We found that best pacing sites typically were located
ar from regions of dense scar; average optimal site location was
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Figure 4 Distribution of LV Pacing Sites Yielding Optimal LV Sy
Ant  anterior; Inf  inferior; Lat  lateral; Sept  septal; other abbreviation as irequently on the opposite LV wall from the infarct zone. rowever, pacing at regions distant from dense infarct zones
as not sufficient for guaranteeing optimal LV mechanical
esponse. Other endocardial sites, equally distant from the
nfarction, did not uniformly yield peak results. Further-
ore, the CS lead position in the 7 patients studied with
RT systems in place was located far from regions of scar,
ut gave demonstrably worse results than the best LV
ndocardial sites. The mechanism by which certain LV
ndocardial sites yield optimal mechanical results does not
ppear to be simply a function of endocardial location per se
r distance from the infarction. Rather, we suspect that
here are variable patterns of conduction velocity, lines of
onduction block, and pacing latency that dictate mechan-
cal effects from stimulation at a certain site. These inputs,
ighly variable among patients, may explain in part the high
ate of CRT nonresponders (particularly in patients with
schemic disease). As we show, however, searching out the
ptimal site(s) for CRT delivery makes these obstacles
urmountable.
Intuitively it would appear that LV pacing at sites of
atest activation should yield maximal mechanical response,
ut we did not find this to be the case. In the majority of
atients, optimal pacing sites were located in regions acti-
ated neither extremely early nor late during ventricular
xcitation. The lack of correlation between latest endocar-
ial activation sites and optimal pacing sites may reflect a
isconnect between electrical and mechanical activation, the
mpact of regions of slow conduction and lines of conduc-
ion block on optimal pacing sites, or some combination of
he two. From a practical standpoint, the dissociation
etween regions of late LV activation and best CRT
region
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chieve optimal mechanical results.
tudy limitations. In the current study, we conducted our
rotocol only in patients referred for ventricular tachycardia
r premature ventricular complex ablation (to justify cath-
ter placement in the left ventricle). Our patient cohort,
herefore, may not be representative of the general popula-
ion of patients with ICM and dyssynchronous LV failure.
ecause of the particular entry criteria and the intensive
ature of the pacing protocol, only a small number of
atients (with some variation in congestive heart failure
ymptom burden) were studied. In addition, various refine-
ents of CRT pacing (including varying AV and interven-
ricular delays) could not be investigated. Pacing was per-
ormed in the VDD mode, allowing for fixed AV delays
uring RVA and BiV pacing, but introducing fluctuations
n heart rate as a variable. Finally, we compared the effects
f endocardial and epicardial pacing in patients who had
ndergone long-term CRT, which may have introduced
nknown effects on the mechanical response to pacing in
hat region. That our results are similar to those of Derval et
l. (15) (who studied patients not subjected to long-term
acing) suggests that the effects of previous CRT in this
omparison may be limited.
onclusions
he LV pacing site is a principal determinant of acute CRT
esponse in patients with ICM. LV endocardial pacing, by
llowing access to heretofore inaccessible pacing sites, can
ield substantial improvement in LV mechanics compared
ith traditional CS-based CRT. Until LV endocardial
acing schemes are available, CRT in patients with ICM is
ikely best delivered from a basal LV position.
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